RENX enters its post-earnings stretch in an uncomfortable spot: a Q1 earnings miss just confirmed, short interest still elevated at nearly 8% of the free float, and borrow costs that remain among the most punishing on the market at 377%.
The most immediate development is Thursday's Q1 earnings release. Revenue of $3.96 million beat the $3.25 million estimate — a sharp acceleration from just $18,000 a year ago. But an adjusted EPS loss of $2.14 missed the $1.64 consensus by a wide margin. Net loss hit $9.33 million for the quarter. The result adds a new layer to an already complex story: revenue growth is genuinely explosive, but losses are widening just as fast.
The lending market has been one of the defining features of this stock for weeks. Borrow costs are running at 377% annually — extreme by any standard, but well below the 594% peak reached on April 14. The easing has been gradual and persistent: costs have fallen roughly 32% over the past month. Availability sits at 77% of outstanding short interest, which is tighter than normal but not at the crisis point seen in early April, when availability collapsed toward zero and the stock drew in concentrated short positions. Short interest itself has unwound sharply: it fell 26% over the week to 1.94% of the free float, and is down over 93% from its level a month ago. That dramatic reversal from the April short-position spike — when shorts briefly topped 2.4 million shares versus the current 172,000 — is the clearest sign that the most aggressive bears have been flushed out. The ORTEX short score still registers 71.9, however, placing this firmly in elevated territory and suggesting the residual short base remains committed despite the recent unwind.
The broader context around that April spike is worth noting. On April 3-6, short interest briefly ballooned to 2.7–2.9 million shares, coinciding with the stock's most stressed lending conditions — availability near zero and borrow costs still in the 400–570% range. That episode appears to have resolved as shorts covered aggressively through late April and into May. The $13 million PIPE financing announced on May 5, with up to $87 million in additional capital available on mutual consent, provided a concrete funding anchor. It may have been the catalyst that broke the bearish conviction.
The company's corporate history adds further nuance. A 1-for-20 reverse stock split on March 26 reset the share count sharply, and the full-year 2025 results reported in late March showed revenue of $8.22 million — up from just $207,000 the prior year. That revenue ramp is striking, though a net loss of $15.96 million underscores the gap between top-line growth and profitability. No analyst coverage appears on the record, so there is no Street consensus to anchor valuation. The market cap is a slim $5.2 million, making this a micro-cap name where every flow matters disproportionately.
With the Q1 report now in the market, a secondary earnings event is on the calendar for May 21. The historical pattern for this stock has been violent in both directions: the April 1 announcement produced a 13% gain on the day and a 58% surge over five days, while the April 16 earnings event sent the stock down 9% on the day before recovering 2% across the week. The stock closed at $2.08 on Friday, down 3% on the day but up 2.2% on the week. Down 27% over one month and 45% year-to-date, price momentum is weak even after the recent bounce. What to watch next: whether the revenue beat is enough to attract fresh buying despite the EPS miss, and whether the May 21 event clarifies the funding picture from the PIPE agreement.
See the live data behind this article on ORTEX.
Open RENX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
